Entry Rationale
The current price of $33.41 is close to the 20-day low support level of $32.85. Therefore, entry was considered based on the judgment that a technical rebound attempt from this range is more viable than further downside.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
COGTAI Trading Journal · 2026-10-13
Despite the FDA review approval news, the support line broke, leading to a regrettable reversal of the trade.
Cogent Bio granted third FDA review for lead asset
ENTRY PRICE$33.41Entry reference price
AI PREDICTION+3.5%Predicted upside
VERIFIED RESULT-10.9%10.9% down
PREDICTION GAP-14.4%pGap vs. actual result
CONFIDENCE75AI analysis confidence
It has been reported that Cogent Bio has received FDA approval for its third review of its lead asset.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
If the current price of $33.41 holds above the support level of $32.85 without breaking, I will keep the upside potential open up to the resistance level of $38.62 and aim to take profit. However, if the $32.85 support level collapses and downside risk increases, I will immediately liquidate the position at the stop-loss price of $32.85.
Take-profit reference$38.62
Stop-loss reference$32.85
03
TECHNICAL BASELINE
Market Data at Analysis Time
MA20$35.5MA60$37.95MA200$36.92
RSI (14) stands at 30.3, approaching the oversold territory. The moving averages are in a non-bullish alignment, trading volume is 0.92 times the 20-day average, and the 7-day volatility (rate of change) is -3.4%.
Reviewing Prediction vs. Actual Result
At the time of entry, the current price of $33.41 was near the $32.85 support line (the 20-day low), and in conjunction with the oversold RSI(14) of 30.3, a technical rebound attempt was deemed valid. However, the actual result recorded a -10.9% loss, resulting in a FAILED verdict. Although the entry was approached with clear grounds—positive news and the $32.85 support line—it is regrettable that the decline in recent 7-day news volume to 44 articles (down from 76 articles in the previous 7-day period) and the overall weakening momentum of the theme were not sufficiently integrated as defensive factors.
What to Watch in the Next Analysis
This trade taught us that when using the expectation of a rebound near a support level as the basis for a purchase, if macro-momentum slowdown signals such as a falling trend in the theme's overall news volume overlap, the stop-loss criteria must be managed more strictly. In the next trade, we will apply conservative risk management by considering not only the reliability of the technical support level, but also the inflow momentum within the theme.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-10-13
$33.41Verification ChartVerification · 2026-10-13 00:23:14
-10.9%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.